NATiAS Inc.

Based in Japan, NATiAS Inc. is a biotechnology company specializing in the contract manufacturing of nucleic acids, focusing on active pharmaceutical ingredients and diagnostic primers for the pharmaceutical and biotech sectors. NATiAS Inc. was founded in 2015 and is headquartered in Kobe-shi, Japan.

The company specializes in nucleic acid synthesis and has engaged in one deal, with the latest being a Series B funding round on March 9, 2022. They successfully raised JPY 330 million with investors including Minato Capital, Mitsui Chemicals, and TORAY ENGINEERING Co. ,Ltd. The founder's previous experience and history are not publicly detailed.

NATiAS Inc. specializes in the contract manufacturing of nucleic acids, focusing on active pharmaceutical ingredients (APIs) and diagnostic primers. Their core product, Blockmer®, uses proprietary technology that significantly reduces the nucleic acid synthesis process duration compared to traditional methods. The company serves a range of clients, including pharmaceutical companies, biotechnology firms, and research institutions involved in genomic research and therapeutic developments.

Additionally, NATiAS produces nucleic acid intermediates and collaborates on joint development projects related to nucleic acid synthesis technologies, primarily targeting clients in advanced biopharmaceutical regions like North America and Europe. NATiAS Inc. generates revenue through B2B transactions with pharmaceutical and biotechnology companies that require nucleic acid manufacturing solutions. Their business model incorporates direct sales agreements for their specialized products, including Blockmer® and nucleic acid APIs, which meet specific client requirements.

The company offers customized contracts to ensure clients receive tailored solutions for their development timelines and regulatory needs. Emphasizing quality and efficiency, NATiAS positions its flagship products at a premium value, which reflects the advanced technology and expertise involved in their production. Their revenue structure is supported by a strong client base that seeks innovative nucleic acid solutions for various applications in healthcare and research. In March 2022, NATiAS raised JPY 330 million in Series B funding to support several strategic initiatives.

The funding will be utilized to participate in NOI, acquire VAXIMM's neoantigen-related patents and know-how, and take over existing contracts with partner companies. These actions are expected to enhance their product offerings and market reach. Additionally, NATiAS is planning to expand into new markets, specifically targeting additional regions in North America and Europe within the next 18 months, leveraging their innovative technologies to meet growing demands.